Supriya G. Mohile, Michelle C. Janelsins, and Karen M. Mustian, University of Rochester Medical Center, Rochester; Beverly Canin, Breast Cancer Options, Kingston; Stuart M. Lichtman and William P. Tew, Memorial Sloan Kettering Cancer Center, New York, NY; William Dale, Peggy S. Burhenn, and Arti Hurria, City of Hope, Duarte, CA; Mark R. Somerfield, American Society of Clinical Oncology, Alexandria, VA; Mara A. Schonberg, Beth Israel Deaconess Medical Center, Brookline, MA; Cynthia M. Boyd, Johns Hopkins University School of Medicine, Baltimore, MD; Harvey Jay Cohen, Duke University Medical Center, Durham; Judith O. Hopkins, Novant Health Oncology Specialists; Heidi D. Klepin, Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC; Holly M. Holmes, McGovern Medical School, Houston, TX; and Alok A. Khorana, Cleveland Clinic, Cleveland, OH.
J Clin Oncol. 2018 Aug 1;36(22):2326-2347. doi: 10.1200/JCO.2018.78.8687. Epub 2018 May 21.
Purpose To provide guidance regarding the practical assessment and management of vulnerabilities in older patients undergoing chemotherapy. Methods An Expert Panel was convened to develop clinical practice guideline recommendations based on a systematic review of the medical literature. Results A total of 68 studies met eligibility criteria and form the evidentiary basis for the recommendations. Recommendations In patients ≥ 65 years receiving chemotherapy, geriatric assessment (GA) should be used to identify vulnerabilities that are not routinely captured in oncology assessments. Evidence supports, at a minimum, assessment of function, comorbidity, falls, depression, cognition, and nutrition. The Panel recommends instrumental activities of daily living to assess for function, a thorough history or validated tool to assess comorbidity, a single question for falls, the Geriatric Depression Scale to screen for depression, the Mini-Cog or the Blessed Orientation-Memory-Concentration test to screen for cognitive impairment, and an assessment of unintentional weight loss to evaluate nutrition. Either the CARG (Cancer and Aging Research Group) or CRASH (Chemotherapy Risk Assessment Scale for High-Age Patients) tools are recommended to obtain estimates of chemotherapy toxicity risk; the Geriatric-8 or Vulnerable Elders Survey-13 can help to predict mortality. Clinicians should use a validated tool listed at ePrognosis to estimate noncancer-based life expectancy ≥ 4 years. GA results should be applied to develop an integrated and individualized plan that informs cancer management and to identify nononcologic problems amenable to intervention. Collaborating with caregivers is essential to implementing GA-guided interventions. The Panel suggests that clinicians take into account GA results when recommending chemotherapy and that the information be provided to patients and caregivers to guide treatment decision making. Clinicians should implement targeted, GA-guided interventions to manage nononcologic problems. Additional information is available at www.asco.org/supportive-care-guidelines .
提供有关在接受化疗的老年患者中评估和管理脆弱性的实用指南。
召集了一个专家小组,根据对医学文献的系统评价制定临床实践指南建议。
共有 68 项研究符合入选标准,成为建议的证据基础。
对于接受化疗的≥65 岁患者,应使用老年评估(GA)来识别在肿瘤学评估中未常规捕获的脆弱性。证据支持至少评估功能、合并症、跌倒、抑郁、认知和营养。专家组建议使用工具性日常生活活动来评估功能,使用全面的病史或经过验证的工具来评估合并症,使用一个问题来评估跌倒,使用老年抑郁量表来筛查抑郁,使用 Mini-Cog 或 Blessed 定向-记忆-集中测试来筛查认知障碍,并评估非故意体重减轻来评估营养。建议使用 CARG(癌症和老龄化研究小组)或 CRASH(高年龄患者化疗风险评估量表)工具来估计化疗毒性风险;使用老年-8 或脆弱老年人调查-13 可以帮助预测死亡率。临床医生应使用 ePrognosis 上列出的经过验证的工具来估计非癌症相关的预期寿命≥4 年。GA 结果应应用于制定综合和个体化的计划,为癌症管理提供信息,并识别可干预的非肿瘤问题。与护理人员合作对于实施 GA 指导的干预至关重要。专家组建议临床医生在推荐化疗时考虑 GA 结果,并将信息提供给患者和护理人员,以指导治疗决策。临床医生应实施针对性的、基于 GA 的干预措施来管理非肿瘤问题。更多信息可在 www.asco.org/supportive-care-guidelines 上获得。